article thumbnail

Novel stem cell therapy repairs 'irreversible' corneal damage in clinical trial

Science Daily: Pharmacology News

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the cornea's surface and improvements in vision.

article thumbnail

David Liu receives Breakthrough Prize in Life Sciences

Broad Institute

David Liu receives Breakthrough Prize in Life Sciences By Corie Lok April 5, 2025 Breadcrumb Home David Liu receives Breakthrough Prize in Life Sciences Liu is honored for the development of base editing and prime editing, two gene editing technologies transforming medicine. In 2013, Broad founding director Eric S.

Science 138
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ALS drugs from Denali, Calico come up short, marking more failures for Healey trial

BioPharma Drive: Drug Pricing

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the tally of failed drugs in the innovative “Healey platform trial” to seven.

Trials 321
article thumbnail

Twice-a-Year Injection Gives Women Full Protection Against HIV, Trial Finds

Drugs.com

MONDAY, June 24, 2024 -- Just two injections a year of a new HIV drug protected young women in Africa from infection with the sexually transmitted disease, new trial results show.In announcing the findings, Gilead Sciences Inc. said its HIV.

Trials 279
article thumbnail

Participants of pioneering CRISPR gene editing trial see vision improve

Science Daily: Pharmacology News

About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a new article.

Trials 361
article thumbnail

An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?

BioPharma Drive: Drug Pricing

An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under regulatory scrutiny.

Trials 360
article thumbnail

Cannabinoid CBG reduces anxiety and stress in first human clinical trial

Science Daily: Pharmacology News

A lesser-known cannabinoid that is gaining in popularity Cannabigerol (CBG) effectively reduced anxiety in a clinical trial without the intoxication typically associated with whole plant cannabis. For the study, researchers conducted the first human clinical trial investigating the acute effects of CBG on anxiety, stress and mood.